US pol­i­cy and reg­u­la­to­ry changes im­pact­ing com­mer­cial­iza­tion of cell and gene ther­a­pies

3 years ago

In­no­v­a­tive An­a­lyt­i­cal Ul­tra­cen­trifu­ga­tion Tech­niques for the Char­ac­ter­i­za­tion of AAV Vec­tors

3 years ago

Re­flect­ing on More Than a Decade of Progress on mR­NA Sci­ence

3 years ago

Key Trends in Dig­i­tal Ther­a­peu­tics

3 years ago

In­te­grat­ed ev­i­dence gen­er­a­tion 2.0: A strat­e­gy for every stake­hold­er

3 years ago

Pi­o­neer­ing Click Chem­istry in Hu­mans

3 years ago

How to safe­ly and suc­cess­ful­ly speed your in­jectable in­to the clin­ic

3 years ago

Biotech in­vestors and CEOs see two paths to growth, but are they equal­ly vi­able?

3 years ago

The Fac­tors Dri­ving a Rapid Evo­lu­tion of Gene & Cell Ther­a­py and CAR-T Clin­i­cal Re­search in APAC

3 years ago

A bet­ter way to ex­plore TC­GA da­ta

3 years ago

Ac­cel­er­at­ing To­ward Hu­man Rel­e­vant Non­clin­i­cal Test Meth­ods

3 years ago

Will Com­mu­ni­cat­ing with Per­son­al HCPs Get the In­dus­try Clos­er to More Di­verse and Ful­ly En­rolled Clin­i­cal Tri­als?

3 years ago

IDC: Life Sci­ences Firms Must Em­brace Dig­i­tal Trans­for­ma­tion Now

3 years ago

In­no­v­a­tive MedTech De­mands Spe­cial­ist Clin­i­cal Tri­al Reg­u­la­to­ry Af­fairs and De­sign

3 years ago

Ad­dress­ing the ‘Ca­pac­i­ty Crunch’ with a Scal­able Plat­form Process Ap­proach

3 years ago

Are we clos­er than we think to per­son­al­ized ge­net­ic med­i­cine?

3 years ago

M&A: a crit­i­cal dri­ver for sus­tain­able top-line growth in health­care

4 years ago

Health eq­ui­ty in­no­va­tion must go be­yond the sci­ence

4 years ago

Lead­ing a Rev­o­lu­tion in Can­cer Care Means Fac­ing Health Eq­ui­ty Chal­lenges

4 years ago

Op­ti­miz­ing Cell and Gene Ther­a­py De­vel­op­ment and Pro­duc­tion: How Tech­nol­o­gy Providers Like Corn­ing Life Sci­ences are Spurring In­no­va­tion

4 years ago

Biotech in­vestors: how to find val­ue in a bear mar­ket

4 years ago

Process Plat­forms vs. Cus­tom Process De­vel­op­ment for AAVs and Gene Ther­a­pies

4 years ago

De­cen­tral­iza­tion: An Eth­i­cal Oblig­a­tion

4 years ago

Avoid­ing Cell Ther­a­py Man­u­fac­tur­ing Grid­locks — a Do’s and Don’ts Guide

4 years ago
First page Previous page 2345678 Next page Last page
A service from the Financial Times